These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 19785058)
1. Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals. Karanikas V; Germenis A J BUON; 2009 Sep; 14 Suppl 1():S153-7. PubMed ID: 19785058 [TBL] [Abstract][Full Text] [Related]
2. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]. Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756 [TBL] [Abstract][Full Text] [Related]
3. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of hematological malignancies using dendritic cells. Van de Velde AL; Berneman ZN; Van Tendeloo VF Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412 [TBL] [Abstract][Full Text] [Related]
5. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"]. Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906 [TBL] [Abstract][Full Text] [Related]
6. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874 [TBL] [Abstract][Full Text] [Related]
7. Tumor resistance to CD8+ T cell-based therapeutic vaccination. Huang Y; Shah S; Qiao L Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376 [TBL] [Abstract][Full Text] [Related]
8. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268 [TBL] [Abstract][Full Text] [Related]
9. Immunizing against breast cancer: a new swing for an old sword. Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269 [TBL] [Abstract][Full Text] [Related]
12. Roadmap to a better therapeutic tumor vaccine. Emens LA Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
14. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Xiang J; Chen Y; Moyana T Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205 [TBL] [Abstract][Full Text] [Related]
15. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188 [TBL] [Abstract][Full Text] [Related]
16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
17. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057 [TBL] [Abstract][Full Text] [Related]
18. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239 [TBL] [Abstract][Full Text] [Related]
19. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017 [TBL] [Abstract][Full Text] [Related]
20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]